OCT 04, 2017 08:00 AM PDT
WEBINAR: Hepatitis C Elimination Starts with Diagnosis
SPONSORED BY: Abbott
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: P.A.C.E. CE | Florida CE
11 15 2006

Speakers:
  • Professor of Medicine, University of Paris-Est. Director of the National Reference Center for Viral Hepatitis B, C &D, and the Department of Virology at the Henri Mondor University Hospital
    Biography
      Dr Jean-Michel PAWLOTSKY is Professor of Medicine at the University of Paris-Est. He is the Director of the National Reference Center for Viral Hepatitis B, C and D and of the Department of Virology at the Henri Mondor University Hospital in Créteil, France, and Director of the Academic Department "Viruses, Immunity and Cancers" (INSERM U955). He focuses on teaching and research in virology (primarily hepatitis viruses) and liver oncology. Dr Pawlotsky earned his medical degree in Hepatology and Gastroenterology in 1992. In addition, he earned a Thesis in molecular virology from the University of Paris, France, and he is a graduate in virology from the Pasteur Institute in Paris and microbiology from the University of Paris. Dr Pawlotsky is active in numerous professional societies, and has been acting as the Secretary General of the European Association for the Study of the Liver (EASL) between 2005 and 2009. He is the President of Scientific Commission 4 (CSS4) and Concerted Action 33 (AC33) of the French National Agency for Research on AIDS and Viral Hepatitis (ANRS). Dr Pawlotsky has been an Associate Editor of Hepatology, the official journal of the American Association for the Study of Liver Diseases (AASLD), between 2001 and 2006, and an Associate Editor of Gastroenterology, the official journal of the American Gastroenterological Association (AGA), between 2011 and 2016. He is a member of the Editorial Board of the Journal of Hepatology, Therapeutic Advances in Gastroenterology, and European Gastroenterology and Hepatology Review. Dr Pawlotsky's noted career contributions include the publication of over 500 articles and book chapters in his areas of expertise and over 500 invited lectures at international meetings.

    Abstract:

    DATE:  October 4th, 2017

    TIME:   8:00AM PT, 11:00AM ET, 5:00PM (GMT+2)

    New HCV drugs are now approved which, when used in combination, yield very high rates of cure of HCV infection. The World Health Organization (WHO)'s goal is to eliminate HCV by 2030. This ambitious objective can only be achieved if HCV is screened in people unaware of their infection and when efficient linkage to care strategies are put in place to cure a large proportion of those diagnosed with HCV infection. Virological tools, such as anti-HCV, HCV RNA and HCV core antigen, are of the utmost importance in the patient's care cascade and can be used to optimize linkage to care, in order to achieve the WHO goals by 2030.

    After this webinar, you will be able to:

    • Discuss the importance of the clinical laboratory in reaching the World Health Organization’s elimination goals
    • Understand recent guideline advancements that support Hepatitis C elimination
    • Describe simplified diagnostic processes that support improved access to care

    Show Resources
    Loading Comments...